Drug intelligence / Profile preview

LT-4002

Development stage: Unknown
Lead developer: LTT Bio-Pharma
Modality: Small Molecules
Administration: Ophthalmic

Overview

LT-4002 is a drug repositioning candidate being developed by LTT Bio-Pharma for the treatment of dry eye syndrome. It is an ophthalmic formulation of diclofenac sodium, a nonsteroidal anti-inflammatory drug (NSAID). The drug is designed to address dry eye pathology by suppressing apoptosis in corneal and conjunctival cells triggered by high osmotic pressure in tears. By leveraging the established safety profile of diclofenac in a new ocular indication, LT-4002 aims to provide a novel therapeutic option for patients with dry eye. It has progressed to Phase 3 clinical development.

Other names: diclofenac sodium

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on LT-4002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LT-4002.

Explore the full profile